Provided by Tiger Trade Technology Pte. Ltd.

Amylyx Pharmaceuticals

27.67
+0.46991.73%
Volume:188.84K
Turnover:5.19M
Market Cap:3.49B
PE:-19.34
High:27.89
Open:27.32
Low:27.00
Close:27.20
52wk High:41.14
52wk Low:10.83
Shares:126.00M
Float Shares:110.00M
Volume Ratio:0.81
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4309
EPS(LYR):-1.5305
ROE:-74.73%
ROA:-44.13%
PB:14.58
PE(LYR):-18.08

Loading ...

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)

TIPRANKS
·
Jun 18

Analysts’ Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), Ascendis Pharma (ASND)

TIPRANKS
·
Jun 16

Amylyx to present avexitide Phase 3 LUCIDITY trial design poster at ENDO 2026

Reuters
·
Jun 08

Amylyx Pharmaceuticals shareholders elect Milne, Fonteyne as Class II directors

Reuters
·
Jun 05

HELIOS Wolfram Data And Patient Insights Could Be A Game Changer For Amylyx Pharmaceuticals (AMLX)

Simply Wall St.
·
May 29

Amylyx director Karen Firestone acquires $51,338 of common shares

Reuters
·
May 27

Do HELIOS Data Shift Amylyx (AMLX) From ALS Setback To Broader Rare-Disease Strategy Reboot?

Simply Wall St.
·
May 22

Amylyx announces publication of Phase 2 open-label HELIOS trial data

TIPRANKS
·
May 16

Amylyx posts Phase 2 HELIOS data showing AMX0035 benefits in Wolfram syndrome

Reuters
·
May 16

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label Helios Trial Data for Amx0035 in the Journal of Clinical Investigation

THOMSON REUTERS
·
May 16

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 11

Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), BioAge Labs, Inc. (BIOA) and Pharvaris (PHVS)

TIPRANKS
·
May 10

Stock Track | Amylyx Pharmaceuticals Plummets 8.16% Intraday on Wider-Than-Expected Q1 Loss

Stock Track
·
May 08

Amylyx Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Amylyx Pharmaceuticals Q1 net loss widens more than expected on higher R&D costs

Reuters
·
May 07

Earnings Flash (AMLX) Amylyx Posts Q1 Loss $0.37 a Share, vs. FactSet Est of $0.35 Loss

MT Newswires Live
·
May 07

Amylyx Pharma Q1 EPS $(0.37), Inline, Cash, Cash Equivalents, And Short-Term Investments Were $279.8M, With Expected Cash Runway into 2028

Benzinga Earnings
·
May 07

Amylyx Q1 net loss widens to $41.3 million

Reuters
·
May 07

BRIEF-Amylyx Pharmaceuticals Q1 EPS USD -0.37 Vs. IBES Estimate USD -0.33

Reuters
·
May 07

Amylyx Pharmaceuticals Inc - Cash Runway Expected to Fund Operations Into 2028

THOMSON REUTERS
·
May 07